Big Pharma fight with generic companies for small molecules
Big Pharma's strategy to fight-off upcoming generic competition on small molecule drugs that are facing patent expiration has Big Pharma moving towards the acquistion of biological assets like ONCY's oncolyic virus Immune Molecule Technology Platfrom which is very difficult to copy in a generic format. Furthermore innovative biological products like ONCY's pelareorep are given preferential treatment through the FDA's 12 market exclusivity starting on the day these biological drugs are approved for sale.
Consequently ONCY's Immune Molecule Technology Platform (pelareorep) is an asset that addresses Big Pharma's strategy to have an asset treat multiple disease states as Big Pharma moves their operations towards the immuno-oncology biopharmaceutical space rather than their traditional small molecule focus.
https://www.fiercepharma.com/pharma/novartis-28b-ms-med-gilenya-exposed-generics-short-term-larger-supreme-court-decision-looms